© 2000 The Royal College of Psychiatrists
Book reviews |
Phospholipid Spectrum Disorder in Psychiatry
Edited by Malcolm Peet, Iain Glen and David F. Horrobin
Lomond & Argyll Primary Care NHS Trust, Argyll & Bute Hospital, Lochgilphead, Argyll PA31 8LD
EDITED BY SIDNEY CROWN and ALAN LEE
Carnforth: Marius Press. 1996. 340 pp. £71.60 (hb). ISBN 1-871622-10-7
For those who have considered neurobiological research in psychiatry to be unhelpfully skewed towards neurotransmitter receptors and away from the lipid characteristics of the membrane environment of those receptors, a National Institute of Health workshop in Washington DC in 1998, organised by Joe Hibbeln, was an indication that some balance was being restored. Many of the contributors to that meeting are included in this new book on recent research into aspects of phospholipid biology of relevance to psychiatry.?
 View larger version (114K): [in a new window] [as a PowerPoint slide] |
|
One of the significant developments has been the clinical application of omega-3 fatty acids in schizophrenia (Puri et al, 1998) and in bipolar affective illness (Stoll et al, 1999). The possible reasons for eicosapentaenoic acid (EPA) being psychotropic are explored here by Malcolm Peet, who also contributes on the role in depression of docosahexaenoic acid (DHA), the other omega-3 fatty acid present in large proportion in fish oil. There is no chapter by Stoll on his experience with omega-3 fatty acids in bipolar affective illness and his findings are referred to only in passing. There is no debate on whether there would be an optimum EPA:DHA ratio for supplementation depending on baseline mood.
It is enjoyable to revisit Hibbeln's elegant solution to the cholesterol lowering/violence controversy, and he considers the importance of DHA and EPA in depression, coronary artery disease, multiple sclerosis, insulin resistance and alcoholism. His linking of dietary fatty acid changes over the past 100 years with increasing prevalence of depression and coronary artery disease is of major epidemiological importance for the health of future generations.
For those new to this area, David Horrobin's introductory chapter outlines the necessary biochemistry and the evidence so far accrued for the membrane phospholipid hypothesis of the neurodevelopmental dysfunction in schizophrenia. In the final chapter he presents an original theory on the biochemical changes which allowed the human brain to evolve, postulating that changes in specific genes and in environmental factors facilitated the development of such human characteristics as a large store of subcutaneous fat available for use during starvation, the fatty female breast and the increased size and connectivity of the brain. He ties in the postulated gene changes with the emergence of schizophrenia and dyslexia (for which a wide but coherent definition is presented in a separate chapter) and with the creativity which has led to such major social, cultural and environmental change in recent centuries.
It is inevitable that most emphasis is on schizophrenia since antisocial personality disorder, which may also be a neuro-developmental phospholipid spectrum disorder, has been less well studied and dementia, in the progression of which fatty acid metabolites may be important, also awaits further exploration. The reviews of the potential importance of anti-oxidants and fatty acids in schizophrenia and of the impact of breast feeding on the risk of later development of schizophrenia add support to the view that attention to nutrition from the uterus onwards is important for optimal brain development. This approach has a significance for populations which far outweighs any advance in the receptor-focused approach, no matter how technically sophisticated it has become.
REFERENCES
- Puri B. K., Steiner, R. & Richardson, A. J.
(1998) Sustained remission of positive and negative symptoms
of schizophrenia following treatment with eicosapentaenoic acid.
Archives of General Psychiatry,
55,
188-189.
[Free Full Text] - Stoll, A. L., Severus, W. E., Freeman, M. P., et al
(1999) Omega 3 fatty acids in bipolar disorder: a preliminary
double-blind, placebo-controlled trial. Archives of General
Psychiatry, 56,
407-412.
[Abstract/Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||